JP2019529534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529534A5 JP2019529534A5 JP2019533300A JP2019533300A JP2019529534A5 JP 2019529534 A5 JP2019529534 A5 JP 2019529534A5 JP 2019533300 A JP2019533300 A JP 2019533300A JP 2019533300 A JP2019533300 A JP 2019533300A JP 2019529534 A5 JP2019529534 A5 JP 2019529534A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- tablet
- trifluoromethyl
- amino
- tablet according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 36
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 32
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 32
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 32
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 32
- 229940125904 compound 1 Drugs 0.000 claims description 28
- 239000008109 sodium starch glycolate Substances 0.000 claims description 22
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 22
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 20
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 8
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 8
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 229940057948 magnesium stearate Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- BRQZOOWELDMGOE-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C[C]=N1 BRQZOOWELDMGOE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000013980 iron oxide Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150798A JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384643P | 2016-09-07 | 2016-09-07 | |
| US62/384,643 | 2016-09-07 | ||
| US201762535162P | 2017-07-20 | 2017-07-20 | |
| US62/535,162 | 2017-07-20 | ||
| PCT/US2017/050202 WO2018048847A1 (en) | 2016-09-07 | 2017-09-06 | Tablet compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150798A Division JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529534A JP2019529534A (ja) | 2019-10-17 |
| JP2019529534A5 true JP2019529534A5 (enExample) | 2020-10-22 |
Family
ID=59895401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533300A Pending JP2019529534A (ja) | 2016-09-07 | 2017-09-06 | 錠剤組成物 |
| JP2022150798A Active JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150798A Active JP7487270B2 (ja) | 2016-09-07 | 2022-09-22 | 錠剤組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11389454B2 (enExample) |
| EP (1) | EP3509570A1 (enExample) |
| JP (2) | JP2019529534A (enExample) |
| KR (1) | KR102498693B1 (enExample) |
| CN (2) | CN120501712A (enExample) |
| AU (1) | AU2017324844B2 (enExample) |
| BR (1) | BR112019004356A2 (enExample) |
| CA (1) | CA3036053A1 (enExample) |
| CL (1) | CL2019000573A1 (enExample) |
| CO (1) | CO2019002092A2 (enExample) |
| EC (1) | ECSP19015828A (enExample) |
| IL (1) | IL265126B2 (enExample) |
| MX (1) | MX392941B (enExample) |
| SG (1) | SG11201901873PA (enExample) |
| WO (1) | WO2018048847A1 (enExample) |
| ZA (1) | ZA201901321B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| BR112019004356A2 (pt) * | 2016-09-07 | 2019-05-28 | Celgene Corporation | composições de comprimido |
| WO2020092906A1 (en) * | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) * | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| CN115243690A (zh) * | 2019-11-14 | 2022-10-25 | 新基公司 | 用于治疗癌症的儿科制剂 |
| JP2024525206A (ja) * | 2021-06-23 | 2024-07-10 | ブループリント メディシンズ コーポレイション | 上皮成長因子受容体阻害剤の医薬組成物 |
| WO2024008138A1 (zh) * | 2022-07-07 | 2024-01-11 | 正大天晴药业集团股份有限公司 | 1,3,5-三嗪衍生物的药物组合 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
| AR016827A1 (es) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| US20030158154A1 (en) * | 2001-07-17 | 2003-08-21 | Moshe Fleshner-Barak | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| US20070010465A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| HUE071632T2 (hu) * | 2009-11-09 | 2025-09-28 | Wyeth Llc | Neratinib-maleát tabletta készítmények |
| AU2011293658B2 (en) * | 2010-08-23 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| AU2013207289B2 (en) | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| EP3019490B1 (en) | 2013-07-11 | 2020-06-03 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| EA030428B1 (ru) | 2013-08-02 | 2018-08-31 | Аджиос Фармасьютикалз, Инк. | Терапевтически активные соединения и способы их применения |
| KR102316886B1 (ko) * | 2013-08-02 | 2021-10-19 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적 활성 화합물 및 이의 사용방법 |
| WO2015018060A1 (en) * | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| US9694013B2 (en) * | 2014-09-29 | 2017-07-04 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| AU2016272089B2 (en) * | 2015-06-03 | 2021-02-18 | Triastek, Inc. | Dosage forms and use thereof |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| EP3362057A1 (en) | 2015-10-15 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| EP3362070B1 (en) | 2015-10-15 | 2021-01-27 | Celgene Corporation | Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia |
| EP3383400B1 (en) | 2015-12-04 | 2022-01-05 | Les Laboratoires Servier | Methods of treatment of malignancies |
| MX390396B (es) | 2016-02-26 | 2025-03-20 | Celgene Corp | Enasidenib para usarse en leucemia mieloide aguda recidivante o refractaria. |
| BR112019004356A2 (pt) * | 2016-09-07 | 2019-05-28 | Celgene Corporation | composições de comprimido |
-
2017
- 2017-09-06 BR BR112019004356-0A patent/BR112019004356A2/pt not_active Application Discontinuation
- 2017-09-06 CN CN202510669668.3A patent/CN120501712A/zh active Pending
- 2017-09-06 JP JP2019533300A patent/JP2019529534A/ja active Pending
- 2017-09-06 MX MX2019002697A patent/MX392941B/es unknown
- 2017-09-06 SG SG11201901873PA patent/SG11201901873PA/en unknown
- 2017-09-06 WO PCT/US2017/050202 patent/WO2018048847A1/en not_active Ceased
- 2017-09-06 AU AU2017324844A patent/AU2017324844B2/en active Active
- 2017-09-06 KR KR1020197006492A patent/KR102498693B1/ko active Active
- 2017-09-06 CN CN201780054265.1A patent/CN109715143A/zh active Pending
- 2017-09-06 IL IL265126A patent/IL265126B2/en unknown
- 2017-09-06 US US15/697,199 patent/US11389454B2/en active Active
- 2017-09-06 EP EP17768583.1A patent/EP3509570A1/en active Pending
- 2017-09-06 CA CA3036053A patent/CA3036053A1/en not_active Abandoned
-
2019
- 2019-03-01 ZA ZA2019/01321A patent/ZA201901321B/en unknown
- 2019-03-05 CO CONC2019/0002092A patent/CO2019002092A2/es unknown
- 2019-03-06 CL CL2019000573A patent/CL2019000573A1/es unknown
- 2019-03-06 EC ECSENADI201915828A patent/ECSP19015828A/es unknown
-
2022
- 2022-06-21 US US17/845,807 patent/US20220323447A1/en not_active Abandoned
- 2022-09-22 JP JP2022150798A patent/JP7487270B2/ja active Active
-
2024
- 2024-06-17 US US18/745,080 patent/US20240335450A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529534A5 (enExample) | ||
| US20240360118A1 (en) | Bicyclic Compounds and their Uses | |
| JP7487270B2 (ja) | 錠剤組成物 | |
| JP7456721B2 (ja) | ５－メチル－１－フェニル－２－（１ｈ）－ピリドンの顆粒製剤及びその製造方法 | |
| JP2016525076A5 (enExample) | ||
| JP2019506387A5 (enExample) | ||
| JP2013539794A5 (enExample) | ||
| WO2012164578A1 (en) | Compositions and methods for preparing immediate release formulations of nilotinib | |
| JP2017527602A5 (enExample) | ||
| JP2015529194A5 (enExample) | ||
| JP7665702B2 (ja) | アキシチニブを含有する医薬組成物 | |
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| CN104546776A (zh) | 瑞戈非尼片剂药物组合物和制法 | |
| EP3860605A1 (en) | Crystalline forms and processes of lenvatinib besylate | |
| JP2019535696A (ja) | ピリドン誘導体の医薬組成物およびその製造方法 | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| US11730753B2 (en) | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride | |
| JPWO2022132652A5 (enExample) | ||
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP7226697B2 (ja) | ブロナンセリン含有錠剤 | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| EP3669867A1 (en) | Pharmaceutical composition comprising ibrutinib | |
| US20160015646A1 (en) | Oral delivery system for sorafenib tosylate | |
| JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
| JP2019503366A (ja) | キノリン誘導体またはその塩を含有する医薬組成物 |